These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37804289)

  • 1. Low-Dose Paclitaxel-Coated Balloons for Femoropopliteal Disease: Days of Future Past?
    Biondi-Zoccai G; Spadafora L; Giordano A
    JACC Cardiovasc Interv; 2023 Nov; 16(21):2666-2669. PubMed ID: 37804289
    [No Abstract]   [Full Text] [Related]  

  • 2. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-coated balloon treatment of complex femoropopliteal disease yields favorable and durable outcomes at 5 years.
    Winscott JG; Hillegass WB
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1284-1285. PubMed ID: 36521184
    [No Abstract]   [Full Text] [Related]  

  • 5. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
    JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
    Zeller T; Brodmann M; Micari A; Keirse K; Peeters P; Tepe G; Scheinert D; Jaff MR; Rocha-Singh KJ; Li P; Schmahl R; Ansel GM;
    Circ Cardiovasc Interv; 2019 Jan; 12(1):e007730. PubMed ID: 30630355
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
    Buszman PP; Nowakowski P; Milewski K; Orlik B; Żurakowski A; Ludyga T; Polczyk F; Dębiński M; Jelonek M; Kachel M; Gąsior M; Granada JF; Kiesz RS; Buszman PE
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2436-2438. PubMed ID: 30522679
    [No Abstract]   [Full Text] [Related]  

  • 10. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
    Kavala AA; Kuserli Y; Turkyilmaz S
    Vascular; 2021 Apr; 29(2):260-269. PubMed ID: 32838692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Nerla R; Vadalà G; Castriota F; Grattoni C; Liso A; Russo P; Pantaleo P; Roscitano G; Cremonesi A
    JACC Cardiovasc Interv; 2017 Apr; 10(7):728-734. PubMed ID: 28385412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 15. Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.
    Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1941-9. PubMed ID: 27659572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of Sirolimus- vs. paCLitaxEl-coated balloon angioPlasty In atherosclerotic femoropopliteal lesiOnS (ASCLEPIOS Study): preliminary results.
    Taneva GT; Pitoulias GA; Abu Bakr N; Kazemtash M; Muñoz Castellanos J; Donas KP
    J Cardiovasc Surg (Torino); 2022 Feb; 63(1):8-12. PubMed ID: 35179337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
    Katsanos K; Spiliopoulos S; Paraskevopoulos I; Diamantopoulos A; Karnabatidis D
    J Endovasc Ther; 2016 Apr; 23(2):356-70. PubMed ID: 26823485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results From the COMPARE Trial.
    Steiner S; Schmidt A; Zeller T; Tepe G; Thieme M; Maiwald L; Schröder H; Euringer W; Popescu C; Brechtel K; Brucks S; Blessing E; Schuster J; Langhoff R; Schellong S; Weiss N; Beschorner U; Wittig T; Scheinert D
    JACC Cardiovasc Interv; 2022 Oct; 15(20):2093-2102. PubMed ID: 36265942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update From the Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study.
    Secemsky EA; Song Y; Schermerhorn M; Yeh RW
    Circ Cardiovasc Interv; 2022 Jun; 15(6):e012074. PubMed ID: 35593638
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.